CVS Health (NYSE:CVS) has been given a $77.00 price objective by equities researchers at Citigroup in a research report issued on Tuesday. The brokerage presently has a “neutral” rating on the pharmacy operator’s stock. Citigroup’s target price points to a potential upside of 9.33% from the company’s previous close.
Other equities research analysts have also recently issued reports about the company. Jefferies Group set a $86.00 price objective on CVS Health and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Mizuho set a $90.00 price objective on CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Robert W. Baird reaffirmed a “hold” rating and set a $77.00 price objective on shares of CVS Health in a research note on Friday, October 27th. Loop Capital reissued a “hold” rating on shares of CVS Health in a research note on Friday, October 27th. Finally, Cowen set a $86.00 target price on CVS Health and gave the company a “buy” rating in a research note on Sunday, October 29th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $87.82.
CVS Health (CVS) traded up $0.56 during trading on Tuesday, hitting $70.43. The company had a trading volume of 1,955,029 shares, compared to its average volume of 9,116,009. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52. The company has a market cap of $70,780.00, a P/E ratio of 11.90, a PEG ratio of 1.16 and a beta of 0.92. CVS Health has a 1-year low of $66.45 and a 1-year high of $84.00.
CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm had revenue of $48.39 billion during the quarter, compared to the consensus estimate of $47.54 billion. During the same quarter in the previous year, the company posted $1.71 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. sell-side analysts anticipate that CVS Health will post 6.47 EPS for the current year.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.61% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in CVS. Vanguard Group Inc. grew its holdings in CVS Health by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 76,557,597 shares of the pharmacy operator’s stock worth $6,159,825,000 after acquiring an additional 1,056,265 shares during the period. BlackRock Inc. grew its holdings in CVS Health by 3.8% during the 4th quarter. BlackRock Inc. now owns 66,996,510 shares of the pharmacy operator’s stock worth $4,857,249,000 after acquiring an additional 2,430,476 shares during the period. FMR LLC grew its holdings in CVS Health by 22.0% during the 2nd quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock worth $2,425,920,000 after acquiring an additional 5,446,930 shares during the period. Northern Trust Corp grew its holdings in CVS Health by 5.5% during the 2nd quarter. Northern Trust Corp now owns 15,618,081 shares of the pharmacy operator’s stock worth $1,256,631,000 after acquiring an additional 807,639 shares during the period. Finally, Nordea Investment Management AB grew its stake in shares of CVS Health by 8.4% in the 2nd quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock valued at $1,138,905,000 after buying an additional 1,100,373 shares during the period. 80.81% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “CVS Health (CVS) PT Set at $77.00 by Citigroup” was originally posted by Zolmax and is the sole property of of Zolmax. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://zolmax.com/investing/cvs-health-cvs-given-a-77-00-price-target-by-citigroup-analysts/1942988.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.